Anthem Biosciences (ANTHEM) investor relations material

Executive summary

• Consolidated revenue for FY26 reached INR 22,801.16 million, up 18% year-over-year, with Q4 being the highest revenue quarter ever at INR 6,109 million, up 26% year-over-year.

• EBITDA for FY26 was INR 9,896 million (43.4% margin), up 31% year-over-year; Q4 EBITDA was INR 3,184 million (48.1% margin), up 52% year-over-year.

• PAT for FY26 was INR 5,918 million (26% margin), up 31% year-over-year; Q4 PAT was INR 1,898 million, up 130% year-over-year.

• Maintained a robust net cash position of INR 13,743 million as of March 31, 2026, supporting future growth initiatives.

• Audited financials were approved with an unmodified audit opinion; a final dividend of INR 2.00 per share was proposed.

Financial highlights

• Other income for FY26 was INR 156 million, including forex gains and export incentives.

• Standalone revenue for FY26 was INR 22,713.87 million, with standalone net profit at INR 6,705.64 million.

• Basic EPS (consolidated) for FY26 was INR 10.55, up from INR 8.07 in FY25.

• Net cash generated from operating activities (standalone) was INR 8,894.15 million.

• Gross fixed assets turnover for FY26 was 1.51x.

Outlook and guidance

• Management targets maintaining 20%+ growth in revenue, EBITDA, and PAT, with a focus on building an agile, science-led CRDMO platform.

• Specialty Ingredients segment expected to grow at a similar trajectory as CRDMO.

• GLP-1 segment anticipated to be a significant contributor pending regulatory approvals.

• Continued investment in capacity expansion and advanced manufacturing technologies.